A macrocyclic inhibitor of
![](/images/gifchars/beta2.gif)
-secretase was designed bycovalently cross-linking the P1 and P3 side chains of an isophthalamide-based inhibitor. Macrocyclization resulted in significantly improvedpotency and physical properties when compared to the initial leadstructures. More importantly, these macrocyclic inhibitors also displayedin vivo amyloid lowering when dosed in a murine model.